Posts Tagged ‘brain swelling’
Systematic review finds more clinical harm than benefits in Alzheimer’s “treatments” lecanemab, aducanumab, and donanemab
Study questions benefit of new Alzheimer’s drug (UGA Today): Last summer, the U.S. Food and Drug Administration fully approved the first drug shown to slow the progress of Alzheimer’s. But new research from the University of Georgia suggests that patients and caregivers may not experience any benefit from the drug in their daily lives. The drug, Leqembi,…
Read MoreFour reasons to question “new generation” monoclonal antibody Alzheimer’s drugs such as aducanumab (Aduhelm), lecanemab (Leqembi), donanemab
New Alzheimer’s Drugs Don’t Deserve the Hype (Being Patient): A prominent childhood memory is of my grandparents living with and then dying from dementia. As is universal with dementia, there was a double blow: watching my grandparents lose their identity and seeing the suffering of those closest to them.
Read MorePrice tag for a questionable Alzheimer’s treatment: $109,000 per patient, per year. Unclear yet: For how many years?
The real costs of the new Alzheimer’s drug, Leqembi — and why taxpayers will foot much of the bill (CBS News): The first drug purporting to slow the advance of Alzheimer’s disease is likely to cost the U.S. health care system billions annually even as it remains out of reach for many of the lower-income seniors…
Read MoreGrowing controversy over role of FDA and Medicare in promoting anti-amyloid drugs given limited benefit, high cost, severe side-effects
The War Over Whether Medicare Should Pay For The New Anti-Alzheimer’s Drugs (Forbes): The powerful Alzheimer’s Disease lobby is fighting a multi-billion-dollar battle on two fronts. It is quietly trying to limit restrictions the Food and Drug Administration puts on the use of new drugs aimed at slowing the progression of the brain disease. And…
Read MoreSix guidelines to navigate the Aduhelm controversy and (hopefully) help patients with Mild Cognitive Impairment and early-stage Alzheimer’s Disease
The approval of a controversial new drug for Alzheimer’s disease, Aduhelm, is shining a spotlight on mild cognitive impairment — problems with memory, attention, language or other cognitive tasks that exceed changes expected with normal aging. After initially indicating that Aduhelm could be prescribed to anyone with dementia, the Food and Drug Administration now specifies that…
Read MoreGrowing backlash against the FDA approval of unproven Alzheimer’s treatment Aduhelm, by Biogen
ICER Issues Statement on the FDA’s Approval of Aducanumab for Alzheimer’s Disease (Institute for Clinical and Economic Review): The Institute for Clinical and Economic Review (ICER) believes that the FDA, in approving aducanumab (Aduhelm™, Biogen) for the treatment of Alzheimer’s disease, has failed in its responsibility to protect patients and families from unproven treatments with…
Read More